Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Davignon, Jean Luc ^a,b   Boyer, Jean Frédéric ^a,b   Jamard, Bénédicte ^b   Nigon, Delphine ^a,b   Constantin, Arnaud ^b,c   Cantagrel, Alain ^a,b  

^a Université Paul Sabatier   (France)

^b CHU PURPAN   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD28 ANTIGEN; CD4 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERFERON; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; THYMIDINE; TRITIUM; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MALE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; MIDDLE AGED; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD28; ANTIGENS, VIRAL; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954558744     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3083     Document Type: Article

References (42)

1. Ruderman EM. Current and future pharmaceutical therapy for rheumatoid arthritis. Curr Pharm Des 2005, 11:671-684. 10.2174/1381612053381954, 15720281.
2. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488. 10.1038/nrd1109, 12776222.
3. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008, 159:1217-1228. 10.1111/j.1365-2133.2008.08851.x, 18945310.
4. Camussi G, Albano E, Tetta C, Bussolino F. The molecular action of tumor necrosis factor-alpha. Eur J Biochem 1991, 202:3-14. 10.1111/j.1432-1033.1991.tb16337.x, 1657606.
5. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731-740. 10.1016/0092-8674(89)90676-4, 2647299.
6. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127. 10.1002/art.11137, 12905464.
7. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104. 10.1056/NEJMoa011110, 11596589.
8. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006, 8:R114. 10.1186/ar1994, 1779425, 16859506.
9. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, Antoni C, Stenger S. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119:1167-1177. 10.1172/JCI38482, 2673881, 19381021.
10. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751. 10.1002/art.20311, 15188349.
11. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703. 10.1136/ard.2004.030528, 1755491, 15695534.
12. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701. 10.1002/art.21675, 16508929.
13. Miceli-Richard C, Gestermann N, Amiel C, Sellam J, Ittah M, Pavy S, Urrutia A, Girauld I, Carcelain G, Venet A, Mariette X. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther 2009, 11:R77. 10.1186/ar2708, 2714125, 19470150.
14. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744. 10.1001/jama.2009.146, 19224750.
15. Sissons JG, Carmichael AJ, McKinney N, Sinclair JH, Wills MR. Human cytomegalovirus and immunopathology. Springer Semin Immunopathol 2002, 24:169-185. 10.1007/s00281-002-0104-0, 12503063.
16. Vaz-Santiago J, Lule J, Rohrlich P, Jacquier C, Gibert N, Le Roy E, Betbeder D, Davignon JL, Davrinche C. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 2001, 75:7840-7847. 10.1128/JVI.75.17.7840-7847.2001, 115026, 11483727.
17. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202:673-685. 10.1084/jem.20050882, 2212883, 16147978.
18. Davignon JL, Clement D, Alriquet J, Michelson S, Davrinche C. Analysis of the proliferative T cell response to human cytomegalovirus major immediate-early protein (IE1): phenotype, frequency and variability. Scand J Immunol 1995, 41:247-255. 10.1111/j.1365-3083.1995.tb03560.x, 7871384.
19. Prieur E, Betbeder D, Niedergang F, Major M, Alcover A, Davignon JL, Davrinche C. Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro. Vaccine 1996, 14:511-520. 10.1016/0264-410X(95)00233-Q, 8782349.
20. Vescovini R, Biasini C, Fagnoni FF, Telera AR, Zanlari L, Pedrazzoni M, Bucci L, Monti D, Medici MC, Chezzi C, Franceschi C, Sansoni P. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J Immunol 2007, 179:4283-4291.
21. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003, 101:2686-2692. 10.1182/blood-2002-08-2502, 12411292.
22. Le Roy E, Baron M, Faigle W, Clement D, Lewinsohn DM, Streblow DN, Nelson JA, Amigorena S, Davignon JL. Infection of APC by human cytomegalovirus controlled through recognition of endogenous nuclear immediate early protein 1 by specific CD4(+) T lymphocytes. J Immunol 2002, 169:1293-1301.
23. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044. 10.1056/NEJM199510193331603, 7675046.
24. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922. 10.1182/blood.V99.11.3916, 12010789.
25. Davignon JL, Castanie P, Yorke JA, Gautier N, Clement D, Davrinche C. Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol 1996, 70:2162-2169. 190054, 8642638.
26. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003, 198:903-911. 10.1084/jem.20022058, 2194204, 12975456.
27. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996, 97:2027-2037. 10.1172/JCI118638, 507276, 8621791.
28. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001, 167:3231-3238.
29. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994, 94:749-760. 10.1172/JCI117394, 296155, 8040330.
30. Romagnoli P, Strahan D, Pelosi M, Cantagrel A, van Meerwijk JP. A potential role for protein tyrosine kinase p56(lck) in rheumatoid arthritis synovial fluid T lymphocyte hyporesponsiveness. Int Immunol 2001, 13:305-312. 10.1093/intimm/13.3.305, 11222499.
31. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
32. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40. 10.1002/art.1780390105, 8546736.
33. Choy EH, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005, 44:1414-1421. 10.1093/rheumatology/kei031, 16030080.
34. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol 2007, 179:6514-6523.
35. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 2005, 52:2996-3003. 10.1002/art.21353, 16200579.
36. Komanduri KV, Donahoe SM, Moretto WJ, Schmidt DK, Gillespie G, Ogg GS, Roederer M, Nixon DF, McCune JM. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology 2001, 279:459-470. 10.1006/viro.2000.0697, 11162802.
37. Widmann T, Sester U, Gartner BC, Schubert J, Pfreundschuh M, Kohler H, Sester M. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 2008, 3:e3634. 10.1371/journal.pone.0003634, 2572846, 18982061.
38. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lorthololary O, Mariette X. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60:1884-1894. 10.1002/art.24632, 2921546, 19565495.
39. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006, 21:1366-1371. 10.1111/j.1440-1746.2006.04559.x, 16911678.
40. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002, 14:1393-1395. 10.1097/00042737-200212000-00018, 12468964.
41. Mizuta M, Schuster MG. Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2005, 40:1071-1072. 10.1086/428672, 15825012.
42. Allan-Yorke J, Record M, de Preval C, Davrinche C, Davignon JL. Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection. J Virol 1998, 72:2316-2322. 109531, 9499092.